Author Affiliations: Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts.

Corresponding Author: Maria A. Yialamas, MD, Department of Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (myialamas@bwh.harvard.edu).

Conflict of Interest Disclosures: None reported.


CORRECTION

Language Errors in Text: In the Letter in Reply titled “Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease—Reply,” published December 2, 2019, there were language errors in 2 sentences that altered meaning. The correct sentences should have read: “We agree that negative results from previous trials that included all types of patients with MCI may not be generalizable to the subset of patients with MCI who have positive results on amyloid PET. “Even in appropriate patients with AD dementia for whom randomized clinical trials show evidence of positive treatment effects, these medications have modest benefit and may result in nontrivial harm.” This article was corrected online.


Clarification of False-Positive Reporting Language in an Editorial: In the Editorial titled “Failing Grade for Shared Decision Making for Lung Cancer Screening,” published in the October 1, 2018, issue of JAMA Internal Medicine, language citing an Original Investigation by Kinsinger et al reporting false-positive findings must be clarified. The phrase in the second paragraph of the Editorial that reads “these harms include a 98% false-positive rate” should more correctly read “the proportion of all positive tests that are falsely positive is 98%.” This Editorial has been corrected online.


Clarification of False-Positive Reporting Language in an Original Investigation: In the Original Investigation titled “Implementation of Lung Cancer Screening in the Veterans Health Administration,” published in the March 6, 2017, issue of JAMA Internal Medicine, there was language reporting false-positive findings that must be clarified. In the Results section, first paragraph of the Patient Outcomes subsection, the phrase “The rate of false-positive test results for lung cancer was 97.5%” should more correctly read “The proportion of all positive tests that were falsely positive was 97.5%.” This article has been corrected online. This article was also corrected on March 6, 2017, to fix a typographical error in the Patient Outcomes subsection of the Results section.